Hepatocellular Carcinoma Recurrent Clinical Trial
Official title:
An Exploratory Study of Bevacizumab Combined With FOLFOX4 in the Treatment of Recurrent Hepatocellular Carcinoma (HCC) After Liver Transplantation
This study is a single arm, single center, prospective and open exploratory study. About 15 patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation are expected to be enrolled.Patients will be treated with bevacizumab and FOLFOX4.Treatment was continued until disease progression, development of intolerable toxicities, death, withdrawal of consent, initiation of new antitumor therapy, whichever occurred first.
Bevacizumab biosimilar：7.5mg/kg，IV，D1，Q2W FOLFOX4： 1. Oxaliplatin: 85 mg/m2 , IV, D1，Q2W 2. Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W 3. Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04506398 -
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
|
||
| Recruiting |
NCT03313648 -
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
|
N/A | |
| Recruiting |
NCT05417932 -
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05277675 -
Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
|
N/A | |
| Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04392700 -
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
|
Phase 3 | |
| Terminated |
NCT01009593 -
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Completed |
NCT02423343 -
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT06233708 -
Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
|
||
| Recruiting |
NCT04425226 -
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
|
N/A | |
| Recruiting |
NCT05497453 -
A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05990959 -
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
|